- Immunization of non-human primates (rhesus macaques) with
BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate
that expresses the SARS-CoV-2 spike glycoprotein, resulted in
strong anti-viral effects against an infectious SARS-CoV-2
challenge
- BNT162b2 immunization prevented lung infection in 100% of the
SARS-CoV-2 challenged rhesus macaques, with no viral RNA detected
in the lower respiratory tract of immunized and challenged animals.
The BNT162b2 vaccination also cleared the nose of detectable viral
RNA in 100% of the SARS-CoV-2 challenged rhesus macaques within 3
days after the infection
- The BNT162b2 vaccine candidate induced SARS-CoV-2 neutralizing
antibodies in rhesus macaques, pseudovirus neutralizing antibodies
in mice, and strong, antigen-specific CD4+ and CD8+ T cells in mice
and macaques
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today
announced preliminary preclinical data in mouse and non-human
primate models from their BNT162b2 mRNA-based vaccine program
against SARS-CoV-2, the virus that causes COVID-19 disease. In a
non-human primate preclinical study, immunization with the
BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate,
protected rhesus macaques against SARS-CoV-2 infection. The
manuscript describing these preclinical data is available on a
preprint server at
https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1 and is
concurrently undergoing scientific peer-review for potential
publication.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200909005570/en/
“Collectively, these preclinical results, combined with our
clinical data collected to date, continue to support the promise
and validity of our mRNA-based vaccine program against SARS-CoV-2
and selection of the BNT162b2 candidate, which we believe has the
potential to prevent many millions of COVID-19 cases,” said
Kathrin U. Jansen, Ph.D., Senior Vice President and Head of
Vaccine Research & Development, Pfizer. “We are encouraged
by the data thus far and confident in our progress towards
developing a safe and effective vaccine candidate to help address
this current pandemic.”
“The data we have shared today include the characterization of
our lead candidate BNT162b2, as well as key animal studies that
were the basis for our clinical programs. They have enabled us to
advance BNT162b2 into Phase 3 evaluation,” said Ugur Sahin,
M.D., CEO and Co-founder of BioNTech. “This is another
development milestone for providing a safe and effective potential
vaccine to the global community to help end this pandemic.”
In the preclinical study, BNT162b2 demonstrated protective
anti-viral effects in rhesus macaques, with concomitant high
neutralizing antibody titers and a TH1-biased cellular response in
rhesus macaques and mice. In a viral infection model, macaques that
received two injections with 100 µg BNT162b2 and macaques that
received saline control injections were challenged 55 days after
the second immunization with a very high viral inoculum of
approximately 1 million plaque forming units of SARS-CoV-2, via
both intranasal (nose) and intratracheal (lung) routes.
Immunization with BNT162b2 reduced viral infection with no viral
RNA detected in the lower respiratory tract of the immunized
animals, while in most non-immunized (saline) animals, there was
evidence of viral RNA.
Importantly, BNT162b2 induced potent SARS-CoV-2 neutralizing
antibodies in vaccinated-macaques, and viral antigen-specific CD4+
and CD8+ T cells. Rhesus macaques (2-4-year-old males) were
immunized by intramuscular (IM) immunization with 30 µg or 100 µg
of BNT162b2 or saline control on Days 0 and 21 (2 doses). After two
immunizations, neutralization titers were detectable in rhesus
macaques sera with geometric mean titers of 962 (on Day 35 for the
30 µg group) or 1,689 (on Day 28 for the 100 µg group).
Neutralizing antibody titers persisted to at least day 56, with
higher geometric mean titers (GMTs) than those in a panel of human
convalescent sera. BNT162b2 vaccination elicited a high frequency
of CD4+ T cells that produced IFN-ɣ, IL-2, and TNF-α, and almost no
IL-4 producing CD4+ cells were detectable, indicating a TH1-biased
response, which is an immune profile thought to promote vaccine
safety. BNT162b2 also elicited spike-specific IFN-ɣ producing CD8+
T cell responses, which is thought to promote an anti-viral
effect.
In a preclinical murine model, a single IM immunization of
BNT162b2 (0.2, 1, or 5 µg) generated B-cell and T-cell immune
responses in BALB/c mice, and SARS-CoV-2 pseudovirus neutralizing
activity increased steadily to Day 28, the last day for which
titers are reported. CD4+ and CD8+ T-cells from splenocytes
isolated from BNT162b2-immunized mice were strongly positive for
IFNγ and IL-2, producing high levels of the TH1 cytokines but
minute amounts of TH2 cytokines, suggesting a robust, TH1-biased T
cell adaptive immune response.
Many of these preclinical data and the Phase 1 clinical results
contributed to the decision by Pfizer and BioNTech to commence the
global (except for China) Phase 2/3 safety and efficacy portion of
the clinical study to evaluate potential prevention of COVID-19
disease by BNT162b2. The Phase 2/3 study has enrolled over 25,000
participants 18 to 85 years of age in the U.S., Argentina and
Brazil. Additional enrollment is planned in Germany, Turkey and
South Africa. The study is an event-driven trial.
Pfizer and BioNTech are committed to decreasing health
disparities in underrepresented populations through the clinical
trial process. To that end, many investigator sites are in diverse
communities that have been disproportionately affected by COVID-19
so that individuals who have been most impacted have the
opportunity to participate. The companies are also working together
with investigator sites and advocacy partners to raise awareness
about the importance of participation in this trial.
BNT162b2 remains under clinical study and is not currently
approved for distribution anywhere in the world. Assuming clinical
success, Pfizer and BioNTech are on track to seek regulatory review
for BNT162b2 as early as October 2020 and, if regulatory
authorization or approval is obtained, currently plan to supply up
to 100 million doses worldwide by the end of 2020 and approximately
1.3 billion doses by the end of 2021.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Pfizer Disclosure Notice
The information contained in this release is as of September 9,
2020. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new
information or future events or developments.
This release contains forward-looking information about Pfizer’s
efforts to combat COVID-19, the collaboration between BioNTech and
Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA
vaccine program, and modRNA candidate BNT162b2 (including
qualitative assessments of available data, potential benefits,
expectations for clinical trials and timing of regulatory
submissions, and anticipated manufacturing, supply and
distribution), that involves substantial risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied by such statements. Risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including the ability to meet anticipated clinical
endpoints, commencement and/or completion dates for clinical
trials, regulatory submission dates, regulatory approval dates
and/or launch dates, as well as risks associated with preliminary
data, including the possibility of unfavorable new preclinical or
clinical trial data and further analyses of existing preclinical or
clinical trial data that may be inconsistent with the data used for
selection of the BNT162b2 vaccine candidate and dose level for the
Phase 2/3 study; the risk that clinical trial data are subject to
differing interpretations and assessments, including during the
peer review/publication process, in the scientific community
generally, and by regulatory authorities; whether and when data
from the BNT162 mRNA vaccine program will be published in
scientific journal publications and, if so, when and with what
modifications; whether regulatory authorities will be satisfied
with the design of and results from these and future preclinical
and clinical studies; whether and when any biologics license and/or
emergency use authorization applications may be filed in any
jurisdictions for BNT162b2 or any other potential vaccine
candidates; whether and when any such applications may be approved
by regulatory authorities, which will depend on myriad factors,
including making a determination as to whether the vaccine
candidate’s benefits outweigh its known risks and determination of
the vaccine candidate’s efficacy and, if approved, whether it will
be commercially successful; decisions by regulatory authorities
impacting labeling, manufacturing processes, safety and/or other
matters that could affect the availability or commercial potential
of a vaccine, including development of products or therapies by
other companies; manufacturing capabilities or capacity, including
whether the estimated numbers of doses can be manufactured within
the projected time periods indicated; whether and when additional
supply agreements will be reached; uncertainties regarding the
ability to obtain recommendations from vaccine technical committees
and other public health authorities and uncertainties regarding the
commercial impact of any such recommendations; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2019 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
About BioNTech
Biopharmaceutical New Technologies is a next generation
immunotherapy company pioneering novel therapies for cancer and
other serious diseases. The Company exploits a wide array of
computational discovery and therapeutic drug platforms for the
rapid development of novel biopharmaceuticals. Its broad portfolio
of oncology product candidates includes individualized and
off-the-shelf mRNA-based therapies, innovative chimeric antigen
receptor T cells, bi-specific checkpoint immuno-modulators,
targeted cancer antibodies and small molecules. Based on its deep
expertise in mRNA vaccine development and in-house manufacturing
capabilities, BioNTech and its collaborators are developing
multiple mRNA vaccine candidates for a range of infectious diseases
alongside its diverse oncology pipeline. BioNTech has established a
broad set of relationships with multiple global pharmaceutical
collaborators, including Genmab, Sanofi, Bayer Animal Health,
Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and
Pfizer. For more information, please visit www.BioNTech.de.
BioNTech Forward-looking statements
This press release contains “forward-looking statements” of
BioNTech within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements may include,
but may not be limited to, statements concerning: BioNTech’s
efforts to combat COVID-19; the potential locations of sites and
participants in our Phase 2b/3 trial; the collaboration between
BioNTech and Pfizer to develop a potential COVID-19 vaccine; our
expectations regarding the potential characteristics of BNT162b2 in
our Phase 2b/3 trial and/or in commercial use based on data
observations to date; the timing for any potential emergency use
authorizations or approvals; and the ability of BioNTech to supply
the quantities of BNT162 to support clinical development and, if
approved, market demand, including our production estimates for
2020 and 2021. Any forward-looking statements in this press release
are based on BioNTech current expectations and beliefs of future
events, and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to:
competition to create a vaccine for COVID-19; the ability to
produce comparable clinical results in larger and more diverse
clinical trials; the ability to effectively scale our productions
capabilities; and other potential difficulties. For a discussion of
these and other risks and uncertainties, see BioNTech’s Annual
Report on Form 20-F filed with the SEC on March 31, 2020, which is
available on the SEC’s website at www.sec.gov. All information in
this press release is as of the date of the release, and BioNTech
undertakes no duty to update this information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200909005570/en/
Pfizer Contacts: Media Relations Jerica Pitts +1 (212)
733-1226 Jerica.Pitts@pfizer.com
Investor Relations Chuck Triano +1 (212) 733-3901
Charles.E.Triano@Pfizer.com
BioNTech Contacts: Media Relations Jasmina Alatovic +49
(0)6131 9084 1513 or +49 (0)151 1978 1385 Media@biontech.de
Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074
Investors@biontech.de
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024